Epic Sciences

Press Releases

05.08.2017

Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors.

Investigators from Yale, USC, UC San Diego, and Epic Sciences published findings in Cancer Epidemiology, Biomarkers & Prevention, showing that the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patients is prognostic of poor survival when patients are treated with standard of care therapeutics not including PD-1 inhibitors.

04.28.2017

Epic Sciences announces completion of $40 million Series D financing.

Epic Sciences announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing.

01.06.2017

Study from MSK and Epic Sciences shows only nuclear-localized AR-V7 Is predictive of therapy benefit for patients with metastatic prostate cancer.

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostatE cancer (mCRPC) patient blood samples is predictive of therapeutic benefit.

11.16.2016

Epic Sciences validates single CTC sequencing, identifies clonal heterogeneity in metastatic cancer.

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC).

11.16.2016

Liquid biopsy biomarker identifies patients with improved response to PARP inhibition in metastatic castrate resistant prostate cancer.

Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors (ARSi) compared to those treated with ARSi alone (overall response rate of 93 percent vs. 22 percent).

11.15.2016

Epic Sciences to present at the Canaccord Genuity Medical Technology & Diagnostics Forum.

Epic Sciences, Inc. a private biotech company that designs and develops predictive tests of therapy response in cancer, announced today that Murali K. Prahalad, Ph.D., chief executive officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at 10:20 a.m. EST. The conference will be held at the Westin Grand Central in New York.

10.25.2016

Epic Sciences to contribute to Cancer Moonshot Blood Profiling Atlas.

Epic Sciences will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit.